METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for Dementia (MET-FINGER)
Cognitive Decline, Cognitive Impairment, Dementia
About this trial
This is an interventional prevention trial for Cognitive Decline focused on measuring Dementia prevention, FINGER multidomain lifestyle intervention, Metformin, World-Wide FINGERs, Drug repurposing
Eligibility Criteria
Inclusion Criteria:
Main inclusion criteria (all participants)
- Age 60-79 years.
- Cardiovascular Risk Factors, Aging and Dementia (CAIDE) Risk Score ≥6 points.
- Cognitive performance at the mean level or slightly lower than expected for age according to local population norms based on the Montreal Cognitive Assessment (MoCA) test and the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) verbal learning test.
- Proficiency in the local language (English, Finnish or Swedish)
Inclusion criteria for metformin/placebo treatment (only for participants in the FINGER 2.0 multimodal lifestyle-based intervention arm)
- No diagnosed diabetes or known contraindications to metformin treatment.
- Elevated adiposity (BMI≥25 kg/m2 OR waist circumference > 102 cm in men and > 88 cm in women) OR mildly impaired fasting glucose (6.1-6.9 mmol/l).
Exclusion Criteria:
Main exclusion criteria (all participants)
- Dementia or substantial cognitive impairment (e.g., memory clinic referral needed as judged by the study physician).
- Current or past use of medications for Alzheimer's Disease or related diseases (e.g., cholinesterase inhibitors, memantine, aducanumab).
- Diminished decision-making capacity, not capable of consenting or completing study assessments, based on clinical judgement.
- Other known significant neurologic disease (including e.g., Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumour, progressive, supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma with persistent neurologic sequelae or known structural brain abnormalities).
- Any other condition affecting safe engagement in the intervention (e.g., malignant disease, major depression, symptomatic cardiovascular disease, revascularisation within the previous year).
- Severe loss of vision, hearing, or communicative ability; conditions preventing cooperation.
- Coincident participation in the active phase of another intervention trial.
- A member of the household already enrolled in the MET-FINGER trial
Exclusion criteria for metformin/placebo treatment (only for participants in the FINGER 2.0 multimodal lifestyle-based intervention group)
- Use of metformin for any indication.
- History of intolerance to metformin used for any indication.
- Diabetes diagnosed or suspected at baseline (e.g., HbA1c≥6.5%, fasting glucose ≥7 mmol/l, or 2HPG≥11.1 mmol/l).
- Metformin contraindications, e.g., history/presence of known renal or liver disease, congestive heart failure, alcohol abuse, calculated Glomerular Filtration Rate<60 ml/min.
Sites / Locations
- Finnish Institute of Health and Welfare - THL
- Karolinska Institutet
- Ageing Epidemiology Research Unit, Imperial College LondonRecruiting
Arms of the Study
Arm 1
Arm 2
Sham Comparator
Active Comparator
Self-guided multidomain lifestyle intervention
FINGER 2.0 multidomain lifestyle-based intervention
In this group, participants will build their own healthy lifestyle program based on standard healthy lifestyle advice that they will receive at individual consultations with the study physician/nurse as part of the study visits, covering four main components (diet, physical activity, cognitive training, and cardiovascular/metabolic risk monitoring). The intervention duration is 2 years.
Within this group, participants will receive a structured intensive lifestyle intervention through individual consultations and group meeting sessions. Four main lifestyle components will be included (diet, physical activity, cognitive training, and cardiovascular/metabolic risk monitoring) as well as social interaction through the group meetings/sessions. In this group, participants eligible for metformin treatment will be further randomised to either: 2000mg/day 1000mg/day placebo. Metformin and placebo will be dispensed every 3 months, both administered orally. The intervention duration is 2 years